Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity and other metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the histaminergic H1 receptor (H1R) has been identified as one of the main contributors to weight gain/obesity side-effects. The effects and mechanisms of betahistine (a histaminergic H1R agonist and H3 receptor antagonist) have been investigated for ameliorating SGA-induced weight gain/obesity in both animal models and clinical trials. It has been demonstrated that co-treatment with betahistine is effective in reducing weight gain, associated with olanzapine in drug-naïve patients with schizophrenia, as well as in the animal models of both drug-naïve rats and rats with chronic, repeated exposure to olanzapine. Betahistine co-treatment can reduce food intake and increase the effect of thermogenesis in brown adipose tissue by modulating hypothalamic H1R-NPY-AMPKα (NPY: neuropeptide Y; AMPKα: AMP-activated protein kinase α) pathways, and ameliorate olanzapineinduced dyslipidaemia through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1: Sterol regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) in the liver. Although reduced locomotor activity was observed from antipsychotic treatment in rats, betahistine did not affect locomotor activity. Importantly, betahistine co-treatment did not influence the effects of antipsychotics on serotonergic receptors in the key brain regions for antipsychotic therapeutic efficacy. However, betahistine co-treatment reverses the upregulated dopamine D2 binding caused by chronic olanzapine administration, which may be beneficial in reducing D2 supersensitivity often observed in chronic antipsychotic treatment. Therefore, these results provide solid evidence supporting further clinical trials in treating antipsychotics-induced weight gain using betahistine in patients with schizophrenia and other mental disorders.
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Introduction
Second generation antipsychotic drugs (SGAs), also called "atypical antipsychotics", are currently the first line of treatment for schizophrenia and other serious mental disorders, with fewer extrapyramidal symptoms (EPS) side-effects at clinically effective doses compared with first generation antipsychotics (FGAs) [1] [2] [3] [4] . However, SGAs such as olanzapine and clozapine are associated with much more severe weight gain/obesity side-effects, and with other common metabolic disorders such as dyslipidaemia, gluco-metabolic abnormalities, insulin resistance, and even type II diabetes [5] [6] [7] . They are currently of great interest to clinicians due to their widespread use in clinics [8] [9] [10] Previous studies have reported various intervention strategies to reduce SGA-induced weight gain [15] [16] [17] . Regarding pharmacological interventions, a number of drugs have been trialled with some success in partially ameliorating SGA-induced weight gain side-effects. A metaanalysis study examined 25 pharmacologic weight loss intervention trials (n=1221) and revealed that amantadine, metformin, reboxetine, sibutramine and topiramate were effective in partially reducing SGA-induced weight gain [18] . Another meta-analysis of 32 placebocontrolled pharmacologic intervention trials involving 1482 subjects suggested that metformin had the most promising effect on weight loss, followed by fenfluramine, sibutramine, topiramate, and reboxetine [19] . Other clinical trials also showed a similar effect of metformin in attenuating SGA-induced weight gain [18, [20] [21] [22] [23] . A recent study reported that both metformin and berberine treatment did not affect food intake, but significantly prevented olanzapine-induced brown fat loss [24] . The same author further found that uncoupled protein-1 (UCP 1 ) expression was significantly increased after co-treatment of metformin and olanzapine, compared with olanzapine only treatment [24] . In addition, metformin and rosiglitazone can also reduce glucose intolerance and insulin resistance in patients treated with SGAs [25, 26] . The potential of zoisamide, sibutramine and topiramate have also been addressed as adjuvant treatments for weight loss of schizophrenic patients treated with SGAs [27-29, 17, 30-32] .
However, to date, these pharmacological intervention studies were not based on the mechanisms of SGA-induced weight gain, particularly considering H 1 R and 5-HT 2C R as the key contributors. Therefore, it is important to investigate the potential for targeting these receptors to control SGA-induced weight gain. In view that histaminergic system could be a target for preventing obesity [33] , this paper reviewed recent reports from both animal and clinical studies on exploring the potential of betahistine (an H 1 R agonist and H 3 receptor (H 3 R) antagonist) to ameliorate SGA-induced weight gain/obesity, and more importantly summarized recent progresses in the underlying mechanisms for this preventing effects by betahistine co-treatment.
Materials and Methods
The systematic electronic reference search for this review paper was performed using the [34, 35] .
Since histamine cannot cross the blood-brain barrier, it is synthesised in situ in the brain from the precursor amino acid, L -histidine and catalysed by the rate-limiting enzyme histidine decarboxylase (HDC) [36] . Histamine exerts its actions via the specific histaminergic receptors, which have been classified into the H 1 , H 2 , H 3 and H 4 receptor subtypes [37, 38] .
All are G-protein-coupled receptors and widely expressed throughout the body. In the central nervous system (CNS), H 1 Rs are mainly located postsynaptically and are found especially in the hypothalamus, cerebral cortex and limbic system [37, 39] , where they are well documented as involved in the regulation of body weight and food intake. H 2 receptors are also mainly located postsynaptically and are expressed in the hippocampus, amygdala and basal ganglia [37] . H 3 receptors are exclusively located presynaptically and found in the nucleus accumbens (NAc), striatum, basal ganglia, and hypothalamus, and regulate histamine production and release [40, 37] . H 4 receptors are expressed in the hypothalamus and spinal cord [41] .
The neurotransmitter histamine plays a crucial role in the regulation of a wide range of behavioural and physiological functions in humans and animals, such as appetite, drinking, sleep, wakefulness, locomotor activity, learning and memory [37, 34, 42, 33] . In particular, histamine has been implicated in the regulation of energy homeostasis [12, 43, 44] . In other words, elevated hypothalamic histamine signalling contributed to decreased food intake and decreased body weight gain [45] [46] [47] 35] , while reduction in histamine levels was associated with increased body weight gain and food intake [37, 42] . Histamine knockout mice predominantly exhibited obesity with increased visceral adiposity, hyperlipidaemia and decreased glucose tolerance [48, 36, 49] . It has also been reported that SGAs such as olanzapine can directly modulate histaminergic neurotransmission in the hypothalamus, which correlated with the regulation of feeding behaviour in rats [50] . Therefore, the histaminergic system could be a target for preventing obesity and other metabolic disorders [33] .
H 1 R, H 3 R and SGA-induced weight gain
Histaminergic H 1 Rs are highly expressed in the hypothalamic arcuate nucleus (Arc), ventromedial hypothalamic nucleus (VMH) and paraventricular nucleus (PVN) [51] , and are involved in the regulation of food intake and energy expenditure [35, 52] . It has been reported that H 1 R antagonists play a crucial role in increasing appetite and obesity development [12, 53] , which were also observed in H 1 R knockout (KO) mice [51, 54] .
Moreover, deprivation of food predominantly led to activation of H 1 R expression in the hypothalamic Arc [13, 55] . It was confirmed that Intracerebroventricular (ICV) injection of the H 1 R agonist, 2-(3-trifluoromethylphenyl)histamine (FMPH) inhibited food intake [56] . [57, 58, 14, 59] . In particular, H 1 R blockade is recognised as a predominant target for SGA-induced weight gain compared with other receptors [4, 60, 61] . Several animal studies found that olanzapine could modulate histaminergic neurotransmission for the regulation of food intake and weight gain in rats [62, 56, 63] . Olanzapine treatment upregulated mRNA expression and protein levels of hypothalamic H 1 R, which was correlated with hyperphagia and weight gain induced by olanzapine [56, 64, 65] . Similarly, clinical studies demonstrated patients treated with antipsychotics showed a significant correlation between the genetic variants of H 1 R (rs346074 -rs346070), BMI (body mass index) and obesity [66, 67] .
Since histamine cannot pass the blood-brain barrier, direct peripheral H 1 R antagonism by SGA treatment may also contribute to the obesity side-effects [13, 56, 64] . The H 1 R antagonistic affinity of SGAs is significantly correlated not only with increased body weight and adiposity, but also with insulin-resistance in schizophrenia patients [68, 60, 69] . Other antihistamine drugs such as loratadine and cyproheptadine are also associated with increased body weight and hyperplasia [70] [71] [72] [73] . Furthermore, the H 1 R antagonistic affinity of SGAs contributes to fat accumulation via downregulation of lipolysis, while upregulating lipogenesis in white adipose tissue [74] [75] [76] [77] .
In addition to H 1 R, the histaminergic H 3 R is another significant target for regulating food intake and is highly expressed in the TMN of the hypothalamus [12, 78, 79] . Furthermore, H 3 heteroreceptors are also located on non-histaminergic neurons, regulating release of neurotransmitters such as acetylcholine, serotonin and dopamine, and may also be involved in food intake regulation [78, 42, 80, 81] . However, SGAs maintain a very weak antagonistic potency at histaminergic H 3 Rs in the brain [82, 83] . As a result, H 3 R may play an indirect role in regulating the weight gain/obesity side-effects induced by SGAs. For example, it is possible that SGAs can block postsynaptic H 1 Rs, which may then lead to accumulation of histamine in the synaptic cleft [12] (summarised in Figure 1 ). Since the release and synthesis of histamine are regulated by presynaptic H 3 autoreceptors [84, 78] , the accumulated histamine then activates the pre-synaptic H 3 R slowing the synthesis and secretion of histamine and heightening feeding behaviour [85, 12, 78, 80] . On the other hand, it was found that intraperitoneal injection of risperidone immediately increased hypothalamic histamine release, that was regulated by H 3 R [86] .
The role of hypothalamic H 1 R-AMPK signalling in SGA-induced weight gain
Hypothalamic AMP-activated protein kinase (AMPK) is highly expressed in the Arc, PVN, VMH and Lateral hypothalamus (LH) of the hypothalamus [63, 87, 88] . It has been suggested that AMPK activity could be inhibited by histamine in hypothalamic tissue slices, while it is activated by H 1 R antagonist triprolidine in both hypothalamic tissue slices and the hypothalamus of knock-out mice [63] . In addition, it is important to note that hyperphagia in diet-induced obese animals is attributed to the effect of hypothalamic AMPK signalling [89] .
Kahn and colleagues showed that AMPK activity in the hypothalamic Arc and PVN was inhibited by anorexigenic leptin and augmented by orexigenic Agouti-related protein (AgRP) [90] . Hypothalamic AMPK is also involved in feeding regulation and food intake by regulating the AMPK-ACC-Malonyl-CoA-CPT1 axis (ACC: acetyl-CoA carboxylase; CPT1: carnitine palmitoyltransferase 1) [91] [92] [93] [94] . A study using the CT1-1 cell line reported that the protein level of phosphor-AMPK (pAMPK) is activated by the H 1 R antagonist chlorpheniramine, while it is blocked by histamine [95] .
It has been found that olanzapine and clozapine activated hypothalamic AMPK by blocking H 1 Rs to increase food intake and body weight gain [63, 96, 97] . In hypothalamic tissue slices, the level of pAMPK can be enhanced markedly by olanzapine, which indicates that the weight gain/obesity side-effects associated with olanzapine is mediated by activation of hypothalamic AMPK linked to blockade of the histaminergic H 1 R [63] . Further in vivo studies in a rat model showed that the pAMPK level was upregulated by olanzapine administration correlated with changes in weight gain [56, 64, 65] . Additionally, administration of olanzapine by acute ICV infusion increased hypothalamic pAMPK expression [98, 99] . Therefore, besides H 1 R itself, its downstream AMPK signals are also valuable targets for treating SGA-induced weight gain/obesity side-effects [12, 13] (summarized in Figure 1 ).
The role of hypothalamic neuropeptide and regulation of energy homeostasis in SGA-induced weight gain
SGA-induced weight gain is associated with alterations to the neuroendocrine network that controls appetite, food intake and satiety [7, 67] . As mentioned above, the hypothalamic Arc plays a crucial role in appetite and energy homeostasis via activation of 2 distinct neural populations: (1) anabolic/orexigenic neurons expressing Neuropeptide Y (NPY) and AgRP, and (2) catabolic/anorexigenic neurons expressing pro-opiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART) [100] [101] [102] , which are involved in the regulation of SGA-induced weight gain.
The role of NPY and AgRP in SGA-induced weight gain
In the CNS, NPY is mainly synthesized in the hypothalamus, brainstem and anterior pituitary [103] . As the biomarker for obesity, NPY is a major mediator in promoting energy storage [104] , which regulates food intake, fat deposition and metabolism via various G-proteincoupled NPY receptors including NPY receptor subtype 1, 2, and 5 [105, 106] . For example, the NPY receptor sub-type 5 antagonist, Velneperit, has been identified in clinical tests as a potential anti-obesity drug [107, 108] . It has been reported that injection of NPY into the PVN repeatedly led to sustained hyperphagia, body weight gain and fat mass accumulation [109, 110] . In addition, synthesis and secretion of Arc NPY resulted in response to energy deficiency and greater metabolic need such as increased exercise, cold and pregnancy [111] [112] [113] . Moreover, the Arc NPY neurons play a role in integrating peripheral energy signals, such as blood glucose concentration, ghrelin, leptin and insulin [114, 115] . AgRP is synthesised exclusively in the Arc that projects to adjacent hypothalamic regions such as the PVN, DMN and LH [116, 110] . The major function of AgRP is to stimulate feeding by antagonising melanocortins at the MC 3 R (melanocortin 3 receptor) and MC 4 R (melanocortin 4 receptor) in the hypothalamus [117] [118] [119] [120] (summarised in Figure 1) . Polymorphism of the AgRP gene is associated with inherited leanness in humans [121] . Similar to NPY, both leptin deficiency (ob/ob) and leptin receptor mutation (db/db) resulted in overexpression of AgRP in the Arc of mice [122, 118, 123] , which has also arisen from fasting in rats and mice [124] . AgRP is sustained for up to a week after a single ICV injection, compared with the effects of NPY which are sustained over hours [125, 126] . Selective ablation of NPY/AgRPexpressing nuclei in adult mice resulted in acute reduction of feeding [127] .
The effects of SGAs on expression of NPY and AgRP have been investigated in previous studies. Fernø and colleagues demonstrated that short-term exposure to olanzapine (6 days) resulted in upregulated NPY and AgRP expressions in the Arc of both rats fed ad libitum and pair-fed rats [98] . Olanzapine upregulated NPY mRNA expression in a dosage dependent manner in the hypothalamic Arc [128] . Furthermore, increased hypothalamic NPY and AgRP expression were also observed by the study using ICV administration of olanzapine [98, 99] .
It has also been reported that the NPY level was upregulated in short (7 days) and mid-term (15 days) olanzapine treatment in rats [129] . Ak and colleagues also reported that the plasma NPY level was attenuated in first attack psychotic male patients treated with olanzapine [100] , while quetiapine increased the NPY level in cerebrospinal fluid from schizophrenia patients [130] ; these changes in NPY level were associated with SGA-induced weight gain. It has also been reported that clozapine enhanced hypothalamic NPY expression in rats [131, 60] (summarised in Figure 1) . The association between AgRP, fat mass and appetite have been examined and were found to be disrupted in olanzapine-treated patients, but not in patients treated with ziprasidone [132] . Although an early study by Ruano and colleagues reported that a polymorphism (rs1468271) in the NPY gene had no association with body weight gain in patients treated with olanzapine and risperidone [133] , a recent study by Tiwari and colleagues suggested a significant association between the SNPs rs16147, rs5573, and rs5574 in NPY and weight gain in clozapine and olanzapine-treated patients [134] . The same authors also revealed an association of rs6837793, near NPY 5 R, with the weight gain profile in patients treated with risperidone, which supported the role of the NPY system in SGAinduced weight gain. Furthermore, it has been reported that there was significant upregulation of NPY expression in H 1 R-knockout and HDC (the neuronal histamine-synthesising enzyme)-knockout mice compared to wild mice [135] . Therefore, SGAs may regulate NPY signalling through acting at H 1 R directly, and this requires further investigation.
The role of POMC and CART in SGA-induced weight gain
POMC is synthesized from the 285-amino-acid-long polypeptide precursor, and produces peptide hormones including β-endorphins and melanocortin [118, 136, 137] . There are several subtypes of the melanocortin peptides, such as adrenocorticotrophin (ACTH) and alpha-melanocyte-stimulating hormone (α-MSH), which act at G-protein-coupled melanocortin receptors such as the MC 1-5 receptors [118, 138, 139] . In the brain, POMC is mainly expressed in the Arc [138, 140] , and projects to various regions of the hypothalamus [118, 141] . Certain POMC gene mutations may contribute to obesity in healthy human populations [142, 143] , while mouse knockout for POMC also shows the obese phenotype [138, 144] . POMC mRNA expression is reduced by food restriction, while it is increased in overfed rats [145, 146] . Importantly, activation of POMC neurons is regulated by the binding of 5-HT to 5-HT 2 R [100, 147] (summarised in Figure 1) . Additionally, POMC expression in the Arc is also regulated by the dopaminergic system via D 2 R [148, 149] . CART is a peptide (first isolated from the ovine hypothalamus), and is widely distributed throughout the central and peripheral nervous systems [150, 151] . CART protein is encoded by the CARTPT gene, which functions in feeding, reward, stress and pain transmissions [152, 153] . Similar to POMC, CART also downregulates food intake and body weight [154, 155] ; a previous study revealed that CART has an effect on neuronal activities (including the hypothalamic VMH and PVN), which are involved in the neuroplasticity of hypothalamic feeding circuits [156] .
Furthermore, CART interacts with other important mediators such as the cannabinoid CB 1 receptor, insulin and leptin, involved in the regulation of feeding [157, 158, 150] . On the other hand, ICV administration of CART was accompanied by a decrease in plasma insulin and leptin levels and an increase in lipid oxidation, which limits fat storage [159] .
In terms of the effect of SGAs on expression of POMC and CART, it was shown that olanzapine treatment resulted in attenuation of POMC but not CART expression in the hypothalamus of rats [98, 65, 160, 128, 129] . Ak and colleagues also reported that the plasma POMC level was elevated in first attack psychotic male patients treated with olanzapine, but no changes in plasma CART level were observed [100] . It should be noted that olanzapine suppresses POMC expression by blocking 5-HT 2C R, and indirectly blocking 5-HT 1B receptors (5-HT 1B R), while that suppression is abolished by GABA (gamma-aminobutyric acid) neurons [161] (summarised in Figure 1) . However, a recent genetic study reported that neither the POMC single nucleotide polymorphisms (SNPs) (rs6713532, rs1047521, rs3754860) nor the CART SNP (rs10515115, rs3763153, rs3857384, rs11575893, rs16871471) gene variants was associated with weight gain in chronic schizophrenia patients treated with SGAs [162] . On the other hand, a genetic polymorphism study suggested that MC 4 R is relevant to SGA-induced weight gain and related metabolic disorders [163] .
Co-treatment with betahistine to control SGA-induced weight gain

Betahistine and its safety profile
As reviewed above, the antagonistic property of histaminergic H 1 R is the major contributor to SGA-induced weight gain side-effects; therefore, there is great potential for controlling that weight gain by targeting H 1 R. The question is therefore whether an H 1 R agonist could be used to prevent and treat SGA-induced obesity. One candidate is FMPH, a selective H 1 R agonist, which has been shown to reverse SGA-induced hyperphagia after ICV injection [56] . 166 ]. It has been trialled as an anti-obesity drug in clinical trials. A randomised, double-blind placebo-controlled trial reported that 32 mg/day treatment of betahistine in 20 obese female subjects for 28 days resulted in 1.1% weight loss, compared to 0.6% weight gain in the placebo group [167] . Barak and colleagues also reported that 12 weeks' treatment of betahistine (16-48 mg/kg) in 281 adults led to significant weight loss in the subgroup of nonHispanic women ≤50 years old with 48 mg/day betahistine treatment [167] .
Animal trials in betahistine intervention for reducing weight gain in drug naïve or chronic/repeated olanzapine treatment rat models
Several animal studies have reported the effects of co-treatment of betahistine with olanzapine on reducing SGA-induced weight gain. Interestingly, the combined histaminergic H 1 R/H 3 R action of betahistine has been proven to be efficient in increasing satiety and reducing the desire to eat fatty foods in rats [168] (Table 1) . Using the established rat model of olanzapine-induced weight gain, it was found that after short-term (2 weeks) treatment, drug naïve rats treated solely with olanzapine (1 mg/kg, t.i.d.) exhibited significant body weight gain and increased food intake (all p<0.001). However, betahistine only (2.67 mg/kg, t.i.d.) treatment had no effect on weight gain and food intake. Importantly, the O+B cotreatment group exhibited significantly reduced feeding efficiency and body weight (~50% net decrease) compared to the olanzapine only-treated group (p=0.015) in drug-naïve rats [169] (Figure 2A ). Olanzapine treatment also increased white fat mass, but had no effect on water intake [169] . Furthermore, olanzapine reduced locomotor activity of rats, which was significantly correlated with weight gain. These results suggested that reduced activity partially contributed to the weight gain side-effect induced by olanzapine. However, cotreatment with betahistine cannot improve locomotor activities decreased by olanzapine. This finding may be one possible explanation of why betahistine can only partially improve olanzapine-induced weight gain [169] (Table 1) .
It is worth noting that clinical patients suffering with schizophrenia, bipolar disease and other mental disorders often face chronic, even life-time, treatment with antipsychotic drugs [165] .
Since betahistine has a high safety profile and low adverse drug reaction, it is essential to investigate the effectiveness of betahistine in prevention of weight gain and obesity following chronic antipsychotic treatment in schizophrenia and other mental disorders. On the other hand, it is well known that antipsychotics cause a significant body weight gain not only in drug-naïve patients, but also in chronic patients who usually have already had previous antipsychotic exposure [6, 65, 170] . In order to investigate whether chronic co-treatment of O+B would have similar weight-attenuating effects, the effect of co-treatment with betahistine was trialled in a rat model with repeated and chronic exposure to olanzapine [65] .
It is interesting that in a chronic rat model, the significant body weight gain induced by olanzapine-treatment could be reversed following drug withdrawal; however weight gain was resumed after re-introducing olanzapine treatment ( Figure 3A) . It was shown that 6 week cotreatment of olanzapine (1 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly decreased (~51.4%) olanzapine-induced weight gain in rats with repeated SGA exposure.
Furthermore, co-treatment also reduced feeding efficiency, liver and fat mass [65] . In addition, olanzapine-treated rats significantly increased inguinal fat (p<0.001), and periovary, mesentery fat (p<0.05) compared to controls (Table 1) . In addition, a recent study found that chronic olanzapine treatment caused a significant upregulation of the circulating nonesterified fatty acid (NEFA), triglyceride (TG) and hepatic lipid accumulation without altering cholesterol synthesis in rats, while betahistine co-treatment significantly reversed olanzapine-induced plasma TG and circulating NEFA [75] . Overall, the studies provided solid preclinical data for preventing/treating SGA-induced weight gain/dyslipidaemia by betahistine treatment, which provides strong support for further clinical trials to improve SGA (olanzapine) induced obesity and its related metabolic disorders using betahistine cotreatment.
Clinical trials for co-treatment of betahistine and olanzapine for reducing SGAinduced weight gain/obesity
Two clinical studies investigated the effect of betahistine treatment on weight loss in obese (otherwise healthy) subjects. Barak and colleagues conducted a multicentre randomized, placebo-controlled weight loss trial using betahistine (16, 32, 48 mg/day) in 281 obese adults for a 12-week treatment [171] . The overall results revealed that betahistine did not induce significant weight loss in obese participants at the above dosages, while the prevalence of adverse events was low. However, further subgroup analysis revealed that the non-Hispanics women ≤ 50 years old, treated by betahistine (48 mg/day) lost ~4.24 kg body weight, compared with the placebo group (~1.65 kg) (p=0.005) [171] (Table 1) . Another randomized placebo-controlled double-blind trial reported that 24 hours treatment of betahistine (48, 96, or 144 mg/day) had no effect on food intake or appetites [172] , suggesting that long term administration may be the essential factor to reveal the effect of betahistine on energy intake [172] (Table 1) .
There have been several clinical studies investigating the effects of betahistine co-treatment in reducing SGA-induced weight gain/obesity in schizophrenia patients. A small clinical trial (in three first-episode schizophrenia patients) found that betahistine (48 mg t.i.d.) was able to prevent significant weight gain caused by olanzapine treatment (10 mg/day) in a 6 weeks' trial of co-treatment with O+B [173] . In detail, an increase in weight during the initial 2 weeks was observed, followed by no additional weight gain (2 patients) or a minor reduction of body weight (one patient) from week 3 to 6. Overall, no subject gained 7% of baseline weight (a cut-off for clinically significant weight gain) [173] (Table 1) (a selective norepinephrine reuptake inhibitor) for 6 weeks in first episode schizophrenia patients resulted in significantly and clinically attenuated weight gain compared with olanzapine-only treatment (2.02±2.37 and 4.77±3.16kg, respectively, p=0.006) [174] . The corresponding increase in BMI was 0.65±0.75 in the olanzapine/reboxetine/betahistine group and 1.53±0.99 kg/m 2 in the olanzapine/placebo group (p=0.008) [174] (Table 1) . Importantly, there was complementary action in the CNS pathway in combination treatment with betahistine, reboxetine and olanzapine, namely, the weight attenuating effect of this combination was two-fold larger than reboxetine only combination (2.75 kg vs. 1.46 kg) [175, 174] .
Another double-blind study demonstrated that 48 healthy women were treated with one week of betahistine (144 mg/day) or matching placebo, followed by olanzapine administration (7.5 or 10 mg/day) for 3 weeks [176] . The result illustrated that the average weight gain in betahistine and placebo groups was 1.2 and 1.9 kg, respectively (p=0.0489), while 52% of the placebo group gained more than 2.0 kg, compared with only 23% in the treatment group (p=0.043) [176] (Table 1 ). The most recent clinical trial is in progress in evaluating the effects of betahistine on reversing SGA-induced weight gain in adolescents and young adults; 40 individuals with a diagnosis of schizophrenia or other mental disorders aged from 12-18, who have been treated with clozapine, olanzapine, risperidone, or quetiapine for 6 weeks and with at least 2% weight gain will be recruited for this trial [177] (Table 1) .
Overall, betahistine co-treatment has shown clinically meaningful attenuation of olanzapineinduced weight gain without changing the therapeutic effect of these antipsychotics. These clinical findings correspond with the results of animal studies, in which it was demonstrated that the co-treatment with betahistine partially reduced olanzapine-induced weight gain sideeffects [169] . It is worthy to note that histaminergic modulation may counterbalance druginduced overfeeding and weight gain, however it may be ineffective when there is no drugdependent alteration as showed in clinical trials in obese (otherwise health) subjects [172, 171] . Therefore, it is not clear whether it could be useful as a weight-loss medication in obese non-medicated people.
The mechanisms underlying betahistine in reducing antipsychoticinduced weight gain
As discussed above, SGA-induced weight gain may be addressed through the upregulation of hypothalamic H 1 R-AMPKα signalling, and NPY levels, accompanied by downregulation of POMC mRNA expression (summarised in Figure 1) [12, 98, 178, 63-65, 179, 160, 97, 129] .
Additionally, it was also revealed that the expression of BAT UCP 1 and PGC-1α protein levels (biomarkers of thermogenesis) is reduced by chronic olanzapine treatment [65, 180] .
These results both confirmed that decreased energy expenditure and increased food intake/feeding efficiency contributed to increased weight gain induced by chronic olanzapine treatment [65, 180] .
Several studies systematically investigated the mechanisms of olanzapine and betahistine cotreatment on attenuating olanzapine-induced weight gain in the rat brain using both drugnaïve and chronic animal models [64, 65, 75] . In detail, the study using olanzapine-naïve rats with 2 weeks' treatment found that co-treatment of O+B reversed the enhanced H 1 R and AMPK expression induced by olanzapine treatment ( Figure 2B ) [64] . In addition, the O+B co-treatment decreased the pAMPKα/AMPKα ratio (compared with olanzapine only treatment), which was positively correlated with total food intake and H 1 R expression [64] .
These findings were confirmed in the chronic repeated olanzapine-treatment rat model; the olanzapine-only treatment increased hypothalamic H 1 R, pAMPKα and AMPKα expression, as well as AMPK/pAMPK changes correlated with body weight gain, hyperphagia and feeding efficiency [65] (Figure 3B ). They are also confirmed by another study in which acute ICV injection of FMPH (an H 1 R agonist) reduced olanzapine-induced hyperphagia [56] .
Since acute ICV injection of FMPH significantly reduced the olanzapine-induced enhanced AMPKα levels [56] , the effect of co-treatment with betahistine in reversing AMPKα/pAMPKα signalling is through activation of the H 1 Rs (summarised in Figure 1) .
It has been revealed that co-treatment with betahistine attenuates the elevated hypothalamic NPY mRNA expression induced by olanzapine in the mediobasal hypothalamus (including the Arc) ( Figure 2B ) [64] . Moreover, AMPK phosphorylation could be promoted by stimulating orexigenic hormones such as NPY and AgRP [181] . Since there are synaptic interactions between NPY afferents and histamine neurons, and the H 3 R antagonist suppresses NPY induced feeding [182] , it is possible that co-treatment with betahistine may activate histamine H 3 R to inhibit olanzapine-induced hyperphagia by suppressing NPY (summarised in Figure 1) .
It is very interesting that although olanzapine administration decreased the POMC mRNA level, that level was not affected by O+B co-treatment in both betahistine animal studies ( Figure 2B & 3B) [64, 65] , which indicated that betahistine attenuation of olanzapine-induced weight gain was not via the POMC pathway [64, 65] . The result was consistent with previous reports that hypothalamic H 1 R is independent of the POMC-melanocortin 4 receptor pathway in regulation of food intake and body weight [183] ; instead, hypothalamic POMC neurons are regulated by 5-HT 2C R (summarised in Figure 1 ).
In addition, UCP 1 and PGC-1α protein levels (biomarkers for thermogenesis) in brown adipose tissue (BAT) were decreased in rats with drug treatment which indicated a decrease in thermogenesis [65] (Figure 3B ). Chronic co-treatment with betahistine also reversed the attenuated BAT UCP 1 and PGC-1α expressions, which illustrated that the two biomarkers of thermogenesis were involved in the decreased energy expenditure and increased weight gain induced by chronic olanzapine treatment [65] . Furthermore, the negative correlation between hypothalamic pAMPKα, and BAT UCP 1 and PGC-1α levels, is in line with the previous report about hypothalamic AMPK modulating BAT thermogenesis, and UCP 1 and PGC-1α expression [184] [185] [186] [187] .
Overall, the results from the acute experiment suggested that co-treatment with betahistine may reverse olanzapine induced body weight gain via the H 1 R-NPY and H 1 R-pAMPKα pathways ( Figure 2B ; summarised in Figure 1) [64] . The olanzapine induced changes in the hypothalamic H 1 R, pAMPKα, BAT UCP 1 and PGC-1α were reversed by chronic cotreatment of O+B ( Figure 3B ; summarised in Figure 1 ) [65] . Therefore, co-treatment with betahistine may regulate BAT UCP 1 and PGC-1α via the hypothalamic H 1 R and pAMPKα pathway.
Furthermore, olanzapine-only treatment significantly increased NEFA in plasma, sterol regulatory element binding protein 1 (SREBP-1) and its target gene expression such as peroxisome proliferator-activated receptor-α (PPARα) in the liver, while these changes could be ameliorated by O+B co-treatment [75] . The same study also revealed that co-treatment of O+B increased the hepatic AMPKα, PPARα and its responsive molecule CPT1A, but decreased the SREBP-1 protein expression compared with olanzapine treatment [75] . 
Co-treatment with betahistine does not affect the efficacy of antipsychotics
Serotonin receptors are G protein coupled receptors such as 5-HT 2A R and 5-HT 2C R; they play a vital role in the therapeutic effects of SGAs and the pathophysiology of schizophrenia [188, 189] . Studies on 5-HTT gene polymorphism have revealed an association with responses to the therapeutic effects of olanzapine and other SGAs [190, 191] . The dopamine receptor, especially the D 2 R, is essential for the therapeutic effect of antipsychotics [192, 193] . There are three main dopaminergic pathways projecting dopaminergic neurons, the mesolimbic (from VTA to NAc, involved in positive symptoms of schizophrenia), the mesocortical (from VTA to cortex including the PFC and Cg, involved in the negative symptoms and cognitive deficits of schizophrenia), as well as the nigrostriatal pathways (from the SN to the CPu), also involved in the pathophysiology of schizophrenia and antipsychotic treatment [192, 194] .
A key issue is whether co-treatment with betahistine has an impact on the therapeutic effects of antipsychotics. Two studies investigated the effects of olanzapine and betahistine cotreatment on the 5-HT 2A R, 5-HT 2C R, 5-HTT, and D 2 R bindings in the brain regions associated with the therapeutic efficacy of antipsychotics, including the PFC, NAcC, NAcS and Cg, in both drug-naïve and chronic/repeated olanzapine-treated rats [195, 196] .
It was shown that there was significant reduction of 5-HT 2A R binding density by olanzapine in various brain regions including the PFC, Cg, NAcC and NAcS [197, 195, 196, 189, 198] .
More importantly, it was revealed that co-treatment with O+B didn't influence olanzapine's effect on 5-HT 2A R in both short-term/drug-naive and chronic/drug re-exposure studies [195, 196] . As another target for the therapeutic effects of antipsychotics, the 5-HT 2C R could be downregulated by SGA treatment including olanzapine [196, 199, 198] . Furthermore, it was revealed that O+B co-treatment didn't interfere with the downregulation effect of 5-HT 2C R binding density in the PFC, Cg, NAcC and NAcS induced by olanzapine-only administration [196] . Except the 5-HT 2A R and 5-HT 2C R, 5-HTT gene polymorphism studies have revealed an association with responses to the therapeutic effects of olanzapine and other SGAs [190, 191] . In the short-term treatment study, both the olanzapine-only and the O+B co-treatment studies significantly attenuated 5-HTT bindings in the SN and VTA of drug-naïve rats [195] .
Additionally, the chronic study showed that reduced 5-HTT binding density was observed in the PFC, Cg, NAcC and NAcS in the olanzapine-only treatment and in the Cg, and in the Cg and NAcS by co-treatment with betahistine [196] . Thus, these studies revealed that cotreatment with betahistine had a similar effect on 5-HTT bindings compared with olanzapineonly treatment in both studies, although the effect occurred in different brain regions [195, 196] .
Both olanzapine and co-treatment of O+B did not cause any significant changes in D 2 R bindings in any brain regions tested after 2 weeks' treatment [195] . However, in the chronic treatment studies, it was revealed that olanzapine administration upregulated the D 2 R binding levels in the Cg, NAcC, NAcS and CPu [196] , as well as the PFC, CPu and NAc [200] . This antipsychotic-induced D 2 R upregulation could cause "dopaminergic supersensitivity" in clinics [201, 193] , in which long-term/chronic treatment with antipsychotics could enhance vulnerability to psychosis frequently observed after drug withdrawal [201] . Additionally, the up-regulation of D 2 R in the CPu by chronic olanzapine administration is associated with the development of EPS [200] . It is interesting that chronic betahistine-only treatment at a higher dosage (9.6 mg/kg) significantly decreased D 2 R binding in the NAc and CPu, while no change was observed in short-term treatment at a lower dosage (2.67 mg/kg). This difference is possibly attributable to both the difference in dosage and treatment duration (2.67 mg/kg for 2 weeks' study vs. 9.6 mg/kg for 5 weeks' study). It is important to note that olanzapineelevated D 2 R binding in the NAc was reversed by co-treatment with betahistine, which suggests that co-treatment with betahistine may improve therapeutic effects by preventing the "dopaminergic supersensitivity" (vulnerability to psychosis) and EPS caused by chronic antipsychotic treatment [196] .
Importantly, clinical studies revealed that betahistine is well-tolerated and safe for cotreatment with olanzapine to schizophrenia patients, with no interference with the therapeutic effect of antipsychotic such as improvement of positive systems of schizophrenia and general psychopathology [176, 202, 173] . Therefore, betahistine is a safe drug for co-administration with olanzapine for mitigating antipsychotic-induced weight gain/obesity, without influencing their therapeutic action.
Conclusions
The SGAs are the first line antipsychotics prescribed to treat schizophrenia and other mental disorders. However they are associated with troublesome weight gain/obesity side-effects, and other metabolic disorders, which may lead to causes of premature death. Therefore, it is extremely important to prevent and treat weight gain/obesity induced by SGAs. It has been suggested that the histamine H 1 R, its downstream pathways and associated neuropeptide are involved in the SGA-induced weight gain/obesity side-effects [6, 12, 13] . It has been reported that betahistine acts as modulator for the histaminergic system through its H 1 R-agonsitic and H 3 R-antagonsitic properties in the brain [167, 203] . Importantly, both animal studies and clinical trials have shown that co-treatment with betahistine is effective to ameliorate olanzapine-induced weight gain, which acts via modulation of the hypothalamic H 1 R-AMPKα, NPY, and BAT UCP 1 -PGC-1α pathways. Furthermore, co-treatment with betahistine was effective in ameliorating olanzapine-induced dyslipidaemia via modulation of the AMPKα-SREBP-1 and PPARα-dependent pathways in the liver [75] . Therefore, these results not only confirm the importance of these pathways in SGA-induced weight gain/obesity side-effects, but also implicate the pathways as promising targets for pharmacological intervention to reduce the SGA-induced weight gain. On the other hand, it has been also reported that co-treatment with betahistine does not affect the key receptor binding sites for the therapeutic efficacy of olanzapine at serotonergic 5-HT 2A R, 5-HT 2C R and 5-HTT, which is consistent with clinical reports that betahistine did not influence therapeutic efficacy. In addition, chronic betahistine treatment significantly reversed D 2 R binding density enhanced by olanzapine, which suggests further clinical investigations into whether co-treatment with betahistine could improve the efficacy of olanzapine by preventing "dopaminergic supersensitivity" caused by chronic antipsychotic treatment [195, 196] .
Overall, in conjunction with previous preclinical and clinical trials in drug-naïve and repeated SGA administration subjects [169, 65, 174, 173] , it is necessary to conduct further clinical trials to investigate the effects of co-treatment with betahistine on reducing olanzapine- 
